Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:23:00.434Z.
Calculation as of: 2026-10-06T18:23:00.434Z.
Quote observation: 2026-10-06T18:20:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad03cc2eaddb42082332b148aee8d6851fa015397d59a0785f41cacae5aa3ea4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$668.94M
EV/EBIT Ratio
61.09x
TTM Avg
21.67x
3Y Avg
25.85x
5Y Avg
35.25x
Market Cap
$671.75M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $655.89M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $668.01M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $668.22M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.94M | 61.09x | 21.67x | 25.85x | 35.25x |
| ArriVent BioPharma, Inc. (AVBP)vs › | $671.61M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $671.75M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $638.60M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $637.78M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $637.58M | N/A | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $629.58M | 12.43x | 14.57x | 14.57x | 18.55x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
